This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: C77 | Special Copayment Reduction: V193 | 5% copayment (for 5 years from the cancer patient registration date) C77.0 lymph nodes of head, face and neck, C77.1 intrathoracic lymph nodes, C77.2 intra-abdominal lymph nodes, C77.3 axillary and upper limb lymph nodes, C77.4 inguinal and lower limb lymph nodes, C77.5 intrapelvic lymph nodes, C77.8 multiple regions, C77.9 unspecified |
| B. Synonyms | Lymph node metastasis, secondary malignant tumor of lymph nodes, metastatic cervical lymph node cancer, supraclavicular lymph node metastasis, Virchow's node, generalized lymph node metastasis, Regional lymph node involvement, Sentinel lymph node metastasis |
| C. Adult onset | Very high — in almost all adult solid cancers, lymph node metastasis is a key factor in staging and prognosis; follows the age of onset of the primary cancer |
The relationship between lymph nodes and cancer has been understood over several centuries. In ancient Greek medicine, Hippocrates described hard masses in the neck (cancer, karkinos), which is interpreted as one of the earliest records of cancer, including lymph node metastasis. Anatomists of the 17th and 18th centuries precisely described the anatomical structure of the lymphatic system, and in the mid-19th century Virchow proposed the theory of cancer spread through lymph nodes. The finding that enlargement of a left supraclavicular lymph node suggests metastasis of an intra-abdominal malignancy—especially gastric cancer—has been used importantly in clinical practice under the name Virchow's node.
In the early 20th century, William Halsted's radical mastectomy (1894–1907) was based on the theory that en bloc resection of the primary tumor site and surrounding lymph nodes could reduce cancer recurrence. For decades thereafter, extensive lymph node dissection was standard, but in the 1990s, advances in the technique of sentinel lymph node biopsy (SLNB) changed the surgical paradigm. The sentinel lymph node concept was first proposed by Cabanas in penile cancer in 1977, and became a clinical standard as Morton applied it to melanoma in 1992 and Giuliano to breast cancer in 1994. Today, SLNB is a minimally invasive staging method that replaces extensive dissection in breast cancer, melanoma, vulvar cancer, and others.
Lymph node metastasis (C77) arises from lymphatic spread of a primary malignancy. The typical route is invasion of the primary carcinoma into its own lymphatic vessels → migration to regional lymph nodes → growth within the lymph node. Because secondary malignancy of the lymph nodes does not occur without a primary cancer, the 'causes' of C77 fundamentally come down to the causes of the primary malignancy (smoking, radiation, carcinogen exposure, genetic predisposition, etc.). Tumor-side factors influencing the development of lymph node metastasis include tumor size, lymphatic invasion, vascular invasion, tumor differentiation, and molecular subtype. Host-side factors include immune status and anatomical variations of the lymphatic system.
Patterns of lymph node metastasis are predicted by the anatomical location of the primary cancer and its lymphatic drainage pathways. Head and neck squamous cell carcinoma → cervical lymph nodes (levels I–V). Breast cancer → axillary lymph nodes, internal mammary lymph nodes. Lung cancer → mediastinal lymph nodes, supraclavicular lymph nodes. Gastric and colorectal cancer → intra-abdominal lymph nodes (perigastric, mesenteric, para-aortic). Prostate and bladder cancer → intrapelvic lymph nodes. Melanoma → regional lymph nodes (adjacent to the primary site). In gastric, esophageal, lung, and ovarian cancer, a Virchow node due to intra-abdominal lymph node metastasis may develop.
The genetics of lymph node metastasis itself is determined by the molecular abnormalities and metastatic capacity of the primary cancer. The molecular mechanisms that promote the metastatic process—invasion, intravasation, circulation, extravasation, and formation of metastatic foci—form the genetic background of lymph node metastasis. EMT (epithelial–mesenchymal transition): loss of E-cadherin (CDH1 mutation/methylation), increased expression of vimentin/fibronectin, and activation of Snail/Slug/Twist/ZEB transcription factor expression confer motility and invasiveness on cancer cells. HER2 amplification, KRAS mutations, PIK3CA mutations, TP53 mutations, and others are associated with the risk of lymph node metastasis in many primary cancers.
In lymphangiogenesis, the VEGF-C/VEGF-D → VEGFR-3 signaling pathway is key. When the primary tumor secretes VEGF-C/D, peritumoral lymphatic vessels dilate and proliferate, promoting metastasis. As immune evasion mechanisms, increased PD-L1 expression, TGF-β secretion, and induction of FOXP3+ regulatory T cells are involved in immune evasion by metastatic cancer cells in lymph nodes. For sentinel lymph node micrometastasis, analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) is being studied as a new tool for identifying micrometastases. The pharmacogenomic characteristics of the primary cancer—BRCA mutations, MSI status, HER2 status, etc.—apply directly to predicting treatment response of lymph node metastases.
Lymph node metastasis can occur in almost all solid cancers, and the proportion of lymph node-positive (N+) cases at diagnosis varies by cancer type. Head and neck squamous cell carcinoma: cervical lymph node metastasis present in about 50–70% at diagnosis. Breast cancer: axillary lymph node positive in about 20–30% overall. Non-small cell lung cancer: mediastinal lymph node metastasis in about 30–40% at diagnosis. Colorectal cancer: regional lymph node metastasis present in stage III, about 30–40% of all colorectal cancers. Gastric cancer: high incidence in Korea, with a substantial proportion having lymph node metastasis at diagnosis. Melanoma: sentinel lymph node metastasis rate of 15–30% depending on thickness (Breslow depth).
In Korea, the C77 code is used as a lymph node metastasis code in staging records of primary cancers and is rarely tallied independently. However, because a substantial proportion of solid cancers common in Korea, such as gastric, colorectal, lung, and breast cancer, show lymph node metastasis at diagnosis or during treatment, C77 is a classification code encountered very frequently in clinical practice. Lymph node metastasis of unknown primary (C77.9) constitutes part of CUP. Supraclavicular lymph node metastasis (Virchow node) is evaluated importantly in Korean gastric cancer clinics as an indicator of distant metastasis of gastric cancer.
Lymph node metastasis of cancer cells takes place through a multistep process. Step 1 — detachment from the primary tumor: weakening of intercellular adhesion due to E-cadherin loss, acquisition of motility by EMT. Step 2 — lymphatic intravasation: dilatation of peritumoral lymphatics (VEGF-C/D stimulation), degradation of the lymphatic basement membrane by secretion of MMPs (matrix metalloproteinases), entry into lymphatics by amoeboid migration. Step 3 — colonization within the lymph node: landing of cancer cells within the lymph node structure → remodeling of the immune microenvironment → increase in regulatory T cells and M2 macrophages → creation of an immunosuppressive environment → growth of micrometastatic clones.
Lymphotropism: cancer cells migrate to the lymph node in response to specific chemokines within it (CXCL12, CCL21). Expression of CXCR4 (the CXCL12 receptor) and CCR7 (the CCL21 receptor) is known to be the key molecular factor increasing lymphotropism. Immune evasion in the lymph node: PD-L1 expression by tumor cells inhibits PD-1 on T cells within the lymph node, blocking immune attack. In some cancers, metastatic cancer cells in lymph nodes show molecular characteristics different from the primary tumor (clonal evolution), which may be associated with treatment resistance in metastatic lesions.
Symptoms of lymph node metastasis (C77) vary with the location and size of the involved lymph nodes and whether there is neurovascular compression. Painless lymph node enlargement is the most common initial symptom, presenting as a hard, irregular palpable mass in the cervical, supraclavicular, axillary, or inguinal lymph nodes. When enlarged lymph nodes compress adjacent structures, the following symptoms occur: cervical lymph nodes—dysphagia, hoarseness, jugular vein compression (facial edema, cervical venous distension). Intrathoracic lymph nodes—cough, dyspnea, hoarseness (recurrent laryngeal nerve compression), superior vena cava syndrome (upper limb edema, facial edema, headache). Intra-abdominal lymph nodes—symptoms of bowel obstruction, abdominal pain, jaundice (biliary compression), lower limb lymphedema (compression of great vessels).
Intrapelvic lymph nodes—lower limb lymphedema, ureteral compression (hydronephrosis), bladder irritation symptoms. Inguinal lymph nodes—lower limb lymphedema, perineal discomfort. Para-aortic lymph nodes—low back pain, flank pain, inferior vena cava compression. Systemic symptoms: B symptoms (night sweats, fever, weight loss) are characteristic of lymphoma but may also appear with metastatic lymph nodes. Fatigue, anorexia, and weight loss are nonspecific symptoms suggesting advanced metastasis. Pain due to lymph node metastasis generally appears late, and radiating pain may occur with nerve involvement.
On palpation of the cervical, axillary, and inguinal lymph nodes, lymph node enlargement that is firm to hard, with irregular borders, fixed to surrounding tissue, and painless is the typical sign of malignant lymph node metastasis. Unlike infectious lymphadenopathy, metastatic lymph nodes lack fluctuance and tend to be without warmth or redness. Virchow's node (left supraclavicular lymph node enlargement) is a sign of distant metastasis of an intra-abdominal malignancy—especially gastric, colorectal, or pancreatic cancer. Irish node (left axillary lymph node enlargement) suggests metastasis of gastric cancer. Superior vena cava syndrome (SVC syndrome) is an emergency caused by mediastinal lymph node metastasis, presenting with facial edema, cervical venous distension, upper limb edema, headache, and cyanosis.
Lymphedema results from blockage of lymphatic flow by lymph node metastasis or after radiation therapy and is characterized by non-pitting edema of the limbs. On abdominal examination, an abdominal mass may be palpable with mesenteric lymph node metastasis, or tympanic percussion and decreased bowel sounds (with bowel obstruction) may appear. If pleural effusion (dullness to percussion, decreased breath sounds) is found on chest auscultation, lymphatic obstruction due to intrathoracic lymph node metastasis is suspected. Jaundice (yellow discoloration of the sclera and skin) suggests biliary compression due to metastasis to hilar lymph nodes.
There is no independent screening program for lymph node metastasis itself; the purpose of screening is to begin treatment before lymph node metastasis occurs through early detection of the primary cancer. Korea's national cancer screening program (gastric, colorectal, liver, cervical, and breast cancer) plays a key role in early detection before lymph node metastasis. Sentinel lymph node biopsy (SLNB) is the standard method for lymph node staging during surgery for solid cancers without clinical lymph node metastasis (breast cancer, melanoma, vulvar cancer, penile cancer, some gastrointestinal cancers).
In follow-up after treatment of the primary cancer, surveillance of regional lymph nodes using CT, PET-CT, and ultrasound is important for early detection of recurrence. Recently, circulating tumor DNA (ctDNA) testing has been studied as a noninvasive means of early detection of micrometastases, including lymph node metastasis. In head and neck cancer follow-up, PET-CT is sensitive for early detection of residual lymph node metastasis or recurrent lymph nodes after treatment. Ultrasound-guided fine-needle aspiration cytology (US-FNA) is used for histological confirmation of suspicious cervical, axillary, and inguinal lymph nodes.
Diagnosis of lymph node metastasis proceeds in the steps of clinical assessment, imaging, and tissue confirmation. Imaging: CT (neck, chest, abdomen, pelvis) is the first-line test to assess lymph node enlargement, internal structural abnormalities, and compression of adjacent organs. MRI has better soft-tissue resolution than CT for evaluating lymph nodes in the head and neck and pelvic regions. FDG-PET-CT is the most sensitive for functional assessment of lymph node metastasis (increased FDG uptake = metabolically active tumor cells) and is standard especially for pretreatment whole-body staging and assessment of treatment response. In SLNB for melanoma, sentinel lymph node identification is performed using a gamma probe and blue dye.
Tissue confirmation: malignant cells in suspicious lymph nodes are confirmed by ultrasound-guided fine-needle aspiration cytology (US-FNA) or core biopsy. Immunohistochemistry (IHC) of the tissue is performed to determine the histologic type of the primary cancer (adenocarcinoma, squamous cell carcinoma, melanoma, etc.) and to estimate the primary organ (TTF-1, PSA, CK7/CK20, ER/PR, HER2, etc.). Surgical lymph node biopsy is performed when FNA is insufficient for diagnosis. Confirming in lymph node tissue the same molecular abnormalities as the primary cancer (KRAS, BRAF, HER2 amplification, etc.) supports the metastatic origin and is used to decide whether targeted therapy applies. Molecular genetic profiling (NGS) is increasingly used to determine treatment strategy.
Treatment of lymph node metastasis is determined in integration with treatment of the primary cancer, according to the type and stage of the primary cancer and the location and extent of lymph node metastasis. Surgical treatment: regional lymph node dissection is part of standard treatment for head and neck cancer, breast cancer, gastric cancer, colorectal cancer, melanoma, thyroid cancer, and others. In breast cancer, omitting axillary lymph node dissection when sentinel lymph node biopsy is negative has become standard (Z0011 trial). In head and neck cancer, selective regional lymph node dissection or radiation therapy is performed based on post-treatment response assessment. Radiation therapy: regional lymph node irradiation is performed as standard in high-risk head and neck cancer (neck field), breast cancer (infraclavicular field), and rectal cancer (pelvic radiation).
Systemic chemotherapy is the foundation of treatment for systemic disease including lymph node metastasis, and the standard chemotherapy regimen for the primary cancer is applied. Immune checkpoint inhibitors: PD-1/PD-L1 inhibitors are first- or second-line treatment options in advanced stages including lymph node metastasis in many cancers. Anti-HER2 therapy (trastuzumab, pertuzumab, T-DM1, T-DXd) is key for lymph node metastasis of HER2-positive breast and gastric cancer. Lymphedema management is an important conservative treatment after lymph node dissection and includes compression bandaging, manual lymphatic massage, and physical therapy. Noninvasive SLNB-related techniques (fluorescence-guided lymph node detection, magnetic particle-guided SLNB) are advancing in the direction of minimally invasive surgery.
Lymph node metastasis (N+) is one of the most important staging factors worsening prognosis in almost all solid cancers. Its effect on prognosis differs by primary cancer type, but in general the number of metastatic lymph nodes, the location of metastatic lymph nodes (regional vs. distant), and the presence of extracapsular extension (ECE) are important. Breast cancer: 5-year survival about 90% or higher when lymph node negative; about 70–80% with 1–3 positive lymph nodes; about 50–60% with 4 or more positive. Colorectal cancer: lymph node negative (stage II) 5-year survival about 80%; 1–3 positive (stage IIIa–b) about 60–70%; 4 or more (stage IIIc) about 40–50%.
Gastric cancer: in Korea, the number of metastatic lymph nodes in gastric cancer is a key staging element in the JGCA and AJCC TNM classifications, and prognosis worsens stepwise from N1 (1–2 nodes) to N3b (>16 nodes). Head and neck squamous cell carcinoma: 5-year survival about 50% with a single ipsilateral positive lymph node; about 30% with bilateral or contralateral positive lymph nodes; even poorer with extracapsular extension. Melanoma: 5-year survival is significantly reduced when histological N+ is found in clinical N0 (SLNB positive). When lymph node metastasis responds to treatment (complete tumor response), local cure is possible. With advances in immune checkpoint inhibitors and targeted therapy, cases of long-term survival are increasing even in advanced stages including lymph node metastasis.
The key to preventing lymph node metastasis is preventing the development of the primary cancer and treating it before lymph node metastasis occurs through early detection. Participation in Korea's national cancer screening program (gastric, colorectal, liver, cervical, and breast cancer) is the most effective means toward this goal. Smoking cessation reduces the development of various cancers, including lung, head and neck, and bladder cancer, indirectly preventing lymph node metastasis. HPV vaccination contributes to preventing cervical lymph node metastasis through prevention of cervical cancer and HPV-related head and neck squamous cell carcinoma.
Sentinel lymph node biopsy (SLNB) is a diagnostic tool rather than a means of prevention, but it plays a large role as a minimally invasive staging method that reduces unnecessary extensive lymph node dissection and the resulting lymphedema. Early detection and prompt treatment of regional lymph node recurrence through regular follow-up examinations—CT, PET-CT, ultrasound—after treatment of the primary cancer is a preventive strategy against systemic spread of lymph node metastasis. To prevent lymphedema, physical therapy, compression therapy, skin care, and weight maintenance are recommended after lymph node dissection. Strategies to reduce lymph node metastasis before surgery through neoadjuvant chemotherapy or neoadjuvant immunotherapy are also being actively studied and applied.